Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2020 |
Sep. 30, 2020 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Dec. 31, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Mar. 31, 2019 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Product sales | $ 0 | $ 90 | $ 0 | $ 18 | $ 593 | $ 2,361 | $ 1,483 | $ 437 | $ 108 | $ 4,874 |
| Operating cost and expense | ||||||||||
| Cost of product sales | 1,081 | 1,635 | 1,306 | 1,454 | 4,702 | 8,231 | 7,185 | 4,681 | 5,476 | 24,799 |
| Research and development cost | 358 | 210 | 217 | 242 | 315 | 282 | 338 | 620 | 1,027 | 1,555 |
| General and administrative expense | 2,712 | 1,656 | 2,245 | 2,385 | 5,856 | 5,107 | 4,335 | 4,016 | 8,998 | 19,314 |
| Total operating expense | 4,151 | 3,501 | 3,768 | 4,081 | 10,873 | 13,620 | 11,858 | 9,317 | 15,501 | 45,668 |
| Loss from operations | (4,151) | (3,411) | (3,768) | (4,063) | (10,280) | (11,259) | (10,375) | (8,880) | (15,393) | (40,794) |
| Other income and expense | ||||||||||
| Insurance proceeds net of related expenses | 1,479 | 1,722 | (52) | (203) | (792) | 0 | 0 | 0 | 2,946 | (792) |
| Impairment expense | (11,741) | 0 | 0 | 0 | (11,741) | 0 | ||||
| Interest expense | (1,107) | (166) | (164) | (183) | (243) | (142) | (203) | (2,889) | (1,620) | (3,477) |
| Interest and other income | 5 | 18 | 3 | 22 | 45 | 85 | 77 | 63 | 48 | 270 |
| Total other expense, net | (11,364) | 1,574 | (213) | (364) | (990) | (57) | (126) | (2,826) | (10,367) | (3,999) |
| Loss before income tax expense | (15,515) | (1,837) | (3,981) | (4,427) | (11,270) | (11,316) | (10,501) | (11,706) | (25,760) | (44,793) |
| Income tax expense | 0 | 0 | (2) | 0 | 0 | 0 | 0 | (2) | (2) | (2) |
| Net loss | $ (15,515) | $ (1,837) | $ (3,983) | $ (4,427) | $ (11,270) | $ (11,316) | $ (10,501) | $ (11,708) | $ (25,762) | $ (44,795) |
| Weighted average shares outstanding, basic and diluted (in shares) | 62,136,421 | 60,998,971 | 60,136,374 | 59,582,603 | 57,523,283 | 57,053,982 | 50,757,448 | 43,514,225 | 60,861,450 | 52,263,885 |
| Basic and diluted net loss per share (in dollars per share) | $ (0.25) | $ (0.03) | $ (0.07) | $ (0.07) | $ (0.20) | $ (0.20) | $ (0.21) | $ (0.27) | $ (0.42) | $ (0.86) |
| X | ||||||||||
- Definition The amount recovered from insurance, net of related expenses. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). No definition available.
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|